Medcast Series

Millions of Americans live with excessive daytime sleepiness (EDS) caused by narcolepsy or obstructive sleep apnea (OSA), yet many remain undertreated, with gaps in identification, management, and access persisting in clinical practice. In this series, W. Christopher Winter, MD (Charlottesville Neurology and Sleep Medicine), and a clinical pharmacist provide an in-depth discussion on solriamfetol (Sunosi; Axsome), the first and only dopamine-norepinephrine reuptake inhibitor (DNRI) approved specifically for EDS in these conditions.

In this Pharmacy Times MEDCast, Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, examines the pharmacist's role in treating worsening congestion in heart failure with subcutaneous furosemide (Furoscix). The series moves from the clinical problem—why oral furosemide fails when patients need it most—through Furoscix's mechanism, patient selection, and monitoring into how pharmacists coordinate care from identification to discharge and build a diuresis model from scratch. Beavers previews the ReadyFlow autoinjector, a higher-concentration formulation that delivers a dose in seconds rather than 5 hours, and closes with practical takeaways on congestion-monitoring technologies, self-education, and pharmacist advocacy in preventing heart failure readmissions.